Trending...
- Hope Healthcare Services Welcomes Three New Board Members
- Class of 2025 - NYC Basketball Hall of Fame
- NBA Legend Jeremy Lin, Benny Luo and Sy Huq Team Up to Executive Produce Powerful New Short Film "Ayo, Check Up!"
FAYETTEVILLE, Ark. - IndianaStop -- Lineus Medical has been granted five additional international patents for its flagship product, SafeBreak® Vascular, in Korea, Brazil, Australia, India, and China. These patents strengthen Lineus Medical's intellectual property portfolio as the company continues expanding into major healthcare markets worldwide. They also mark a key milestone toward obtaining regulatory clearances and establishing distribution partnerships in these regions.
SafeBreak Vascular is the only break-away device for IV lines clinically proven to reduce IV complications1. When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.
More on indianastop.com
"Securing these new patents is a critical step in advancing the global presence of SafeBreak," said Vance Clement, CEO of Lineus Medical. "They not only protect our product from being copied and add value to the company, they also provide us credibility in establishing relationships with new distribution partners in these countries."
About Lineus Medical:
Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.
References:
1. Data on File
SafeBreak Vascular is the only break-away device for IV lines clinically proven to reduce IV complications1. When a harmful force is placed on the line, SafeBreak intentionally separates to remove the damaging force and protect the patient's IV. When SafeBreak separates, valves on both ends of the device close preventing medicine spills from the pump and blood loss from the patient. To replace SafeBreak, each component is unthreaded from the line, a new sterile SafeBreak is installed, and the patent's infusion is restarted. Patients avoid additional needlesticks, nurses save time, and hospitals save money1.
More on indianastop.com
- The Great Reset, the First Photorealistic AI Film Makes History at the Cannes Film Festival
- MobileX Hits Top Gear at the Indy 500 with Rahal Letterman Lanigan Racing
- Global Patient Organizations Applaud Historic Passage of Integrated Lung Health Resolution at World Health Assembly 78
- Love, Laughter, And Legacy Collide In The Romantic Comedy "different With Me"
- Natalie Jean Releases Heartfelt Tribute Single "What They Didn't See" Honoring Late Friend and Lyricist Michael Peloso
"Securing these new patents is a critical step in advancing the global presence of SafeBreak," said Vance Clement, CEO of Lineus Medical. "They not only protect our product from being copied and add value to the company, they also provide us credibility in establishing relationships with new distribution partners in these countries."
About Lineus Medical:
Lineus Medical is the developer of a break-away technology that is proven to reduce IV restarts and IV complications1. Our mission is to remove the pains associated with medical lines. More information about Lineus Medical can be found at www.lineusmed.com. Follow Lineus Medical on LinkedIn, Facebook, and Instagram.
References:
1. Data on File
Source: Lineus Medical
0 Comments
Latest on indianastop.com
- 150% Increase in Fiscal Q2 Sales vs Previous Year to $750,000; Continuous Record Quarters & Profitability for Homebuilding Product: Innovative Designs
- City of Bloomington Invites Public to Join Focus Groups on Bloomington's Community Identity
- Use Dogecoin (DOGE) to mine Bitcoin (BTC) and earn passive income at home
- ELEVANCE HEALTH SECURITIES FRAUD NOTICE: Berger Montague Informs Elevance Health (NYSE: ELV) Investors of Securities Fraud Lawsuit
- European Tech Startup RoarFun discovers a gap in the U.S. market with a branded racing simulator rental at Atlanta's MRO Americas Aviation Convention
- Degrees of Justice: Attorney Frank Walker Charts the Future of Criminal Justice with Ph.D Degree
- The Jesse Roldan Team and Biz Hub Financial Successfully Facilitate One-Day Closing for Investor Deal in Hellertown, PA
- How Does Google Crawl Websites?
- Perspectives: Jellyfish Publication of an exciting new human clinical trial of proprietary KollaJell™ collagen peptide formulation
- City of Bloomington Releases Updated Resource Guides Covering Healthcare, Housing, and More
- Sequentex Achieves OMNIA Partners Approval, Empowering Public Sector and other Agencies with Streamlined Technology Procurement
- CEO Selected to Present at Wall Street Conference on May 21, 2025 for Suicidal Depression / PTSD: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
- Bloomington: Energy-saving Incentive Programs Available to Help Renters, Landlords, and Homeowners Save Money on Utility Bills
- $10 Million Plan to Acquire Successful Remote Lottery Platform: Expanding Global Footprint into Live Entertainment: Lottery.com (Stock Symbol: LTRY)
- INDIANA FEVER WELCOMES CHICKEN SALAD CHICK TO GAINBRIDGE FIELDHOUSE FOR GAME DAY DINING
- Assent Launches Carbon Border Adjustment Mechanism Solution to Help Manufacturers Meet Regulatory Requirements
- Q1 2025 Revenue Soars 92% to $1.13M on Strategic Acquisitions, Organic Growth & Breakthroughs in AI Drones & Quantum Tech: ZenaTech Stock Symbol: ZENA
- Savista Retreat Announces Monthly Yoga, Wellness & Experiential Retreats in Jaipur
- Robert Tsigler Selected by NADC as Top 1% Attorney in the U.S. for 2025
- **Award-Winning Dystopian Book Series Hitting Too Close to Home**